Loading
A phase 1/2 trial of TST003 in colorectal cancer, run by Transcenta Therapeutics (Hangzhou) Co., Ltd., active and no longer recruiting.
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT05731271 by Transcenta Therapeutics (Hangzhou) Co., Ltd., with 111 participants enrolled, started 2023-02-08 and due to reach its primary completion in 2026-06. Interventions recorded: TST003.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/